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A Human CD4 T Cell Epitope in the Influenza Hemagglutinin Is
Cross-Reactive to Influenza A Virus Subtypes and to Influenza B
Virus
Jenny Aurielle B. Babon,a,b John Cruz,a Francis A. Ennis,a,b Liusong Yin,b,c and Masanori Terajimaa,b
Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USAa; Program in
Immunology and Virology, University of Massachusetts Medical School, Worcester, Massachusetts, USAb; and Department of Pathology, University of Massachusetts
Medical School, Worcester, Massachusetts, USAc
The hemagglutinin protein (HA) of the influenza virus family is a major antigen for protective immunity. Thus, it is a relevant
target for developing vaccines. Here, we describe a human CD4 T cell epitope in the influenza virus HA that lies in the fusion
peptide of the HA. This epitope is well conserved in all 16 subtypes of the HA protein of influenza A virus and the HA protein of
influenza B virus. By stimulating peripheral bloodmononuclear cells (PBMCs) from a healthy adult donor with peptides cover-
ing the entire HA protein based on the sequence of A/Japan/305/1957 (H2N2), we generated a T cell line specific to this epitope.
This CD4 T cell line recognizes target cells infected with influenza A virus seasonal H1N1 and H3N2 strains, a reassortant
H2N1 strain, the 2009 pandemic H1N1 strain, and influenza B virus in cytotoxicity assays and intracellular-cytokine-staining
assays. It also lysed target cells infected with avian H5N1 virus. We screened healthy adult PBMCs for T cell responses specific to
this epitope and found individuals who had ex vivo gamma interferon (IFN-) responses to the peptide epitope in enzyme-
linked immunospot (ELISPOT) assays. Almost all donors who responded to the epitope had the HLA-DRB1*09 allele, a relatively
commonHLA allele. Although natural infection or standard vaccinationmay not induce strong T and B cell responses to this
highly conserved epitope in the fusion peptide, it may be possible to develop a vaccination strategy to induce these CD4 T cells,
which are cross-reactive to both influenza A and B viruses.
Influenza remains an important infectious respiratory disease,causing significant morbidity and mortality around the world
every year. Influenza A virus is the major type of influenza virus
that causes disease in humans, while influenza B virus also causes
disease in humans, although to a less severe extent (51). Influenza
A virus undergoes frequent antigenic drifts at antibody-combin-
ing sites on hemagglutinin (HA) and occasional shifts due to the
emergence of currently circulating strains with novel genes reas-
sorted from nonhuman virus strains into human viruses. These
antigenic drifts/shiftsmake it extremely challenging to design vac-
cines that can protect against emerging antigenically variant influ-
enza viruses. The annual seasonal influenza vaccine requires ac-
curate prediction of influenza virus strains thatwill circulate in the
coming season, and this relies on viral surveillance data (24).
When the vaccine strains do not match the actual circulating
strains for a given influenza season, the immunity generated by
these vaccines is not optimal. To measure vaccine immunogenic-
ity, the hemagglutination inhibition antibody titer in nature or
after vaccination is a correlate of protection and a determinant of
vaccine efficacy. In addition, both CD8 and CD4 T cells to
multiple viral proteins, including HA, also contribute to the im-
mune responses to influenza virus (76).
CD4 T cells are not essential in providing protective immu-
nity in mouse models of influenza infection when both CD8 T
cells and B cells are present (reviewed in reference 9). However,
they play important roles in the immune response to influenza
virus by maintaining the CD8 T cell cytotoxic responses and the
transition to memory phase (6) and by providing help to anti-
body-producing B cells (31). Human CD4 T cell responses to
influenza virus are not well understood. A recent study byWilkin-
son and colleagues demonstrated that memory influenza virus-
specific CD4 T cells contribute to disease protection in a human
influenza virus infection challenge (80).Most of the humanCD4
T cell responses to influenza virus have been mapped to the HA
protein (30). In a genome-wide screening of T cell epitopes to the
influenza virus proteins thatwe recently performed,we found that
the HA and matrix 1 (M1) proteins contained more CD4 T cell
epitopes than other viral proteins (4). We also found individuals
whose T cells responded to theH5 avianHApeptides even though
they had not been previously exposed to H5N1 virus. Other
groups have also found cross-reactive T cells to H5HA in individ-
uals who had not been exposed to avian influenza virus (16, 47, 64,
83). These results suggest that cross-reactive CD4 T cells to the
surface glycoprotein HA are generated by infection and/or vacci-
nation. These CD4 T cells, in turn, have the potential to mediate
protection against a different subtype of influenza A virus.
The influenza HA is amajor antigenic site of protective immu-
nity. It is also indispensable in the viral life cycle because it is
necessary for binding the viral receptor (sialic acid) on target cells
andmediating the fusion of viral and cellularmembranes (15, 68).
HA consists of two subunits, HA1 andHA2, which are products of
the enzymatic cleavage of the precursor protein HA0 (51). The
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majority of the antigenic sites recognized by neutralizing antibod-
ies and subject to antigenic drift are located in the HA1 subunit.
The HA2 subunit, on the other hand, is more conserved among
the different HA subtypes. Recently, an in silico study was done to
evaluate the presence of cross-reactive T cell epitopes in the HA of
seasonal influenza H1N1 and H3N2 viruses and the novel pan-
demic H1N1 virus (20). Duvvuri and colleagues found that CD4
T cell epitopes within different H1N1 strains were significantly
conserved, while there were fewer conserved epitopes between the
H3 and H1 subtypes (20). Although their findings suggest that
cross-reactive T cells recognizing an epitope across all the different
HA subtypesmay be elusive, there are regions in theHA2 subunit,
in particular the fusion peptide sequence, that are highly con-
served in all the different HA subtypes (15).
In this study, we generated a human CD4 T cell line that
recognizes the fusion peptide sequence of the influenza virus HA.
This epitope is well conserved in all 16 types of HA of influenza A
virus and the HA of the influenza B virus. This CD4 T cell line
was able to lyse target cells that are infectedwith influenzaAH1N1
virus, including the novel pandemic H1N1 and the H2N1 and
H3N2 viruses, as well as an influenza B virus. We tested healthy
adult peripheral blood mononuclear cells (PBMCs) against the
various HA peptides and found that donors who had the HLA-
DRB1*09 allele had ex vivo gamma interferon (IFN-) responses
to the epitope, suggesting that this is a major histocompatibility
complex (MHC) restriction allele for the highly conserved se-
quence.
MATERIALS AND METHODS
Influenza viruses, peptides, and proteins. Lyophilized 17-mer peptides
spanning the HAs of influenza A H1N1, H3N2, and H5N1 and influenza
B viruses were obtained from the National Institutes of Health (NIH)
Biodefense and Emerging Infections Research Resources Repository (BEI
Resources, Manassas, VA) and were previously described (4). Peptides
spanning the HA of influenza virus A/Japan/305/1957 (H2N2) were de-
signed to correspond to BEI Resources’ H5HA peptides and were synthe-
sized by AnaSpec, Inc. (San Jose, CA). The peptides were reconstituted by
dissolving them in 100%dimethyl sulfoxide at a stock concentration of 10
mg/ml. Peptide pools were made with 9 or 10 nonoverlapping peptides
per pool at a concentration of 1.1 or 1.0 mg/ml per peptide. Recombinant
HA proteins of A/Singapore/1/1957 (H2N2) and A/Canada/RV444/04
(H7N3) were obtained from BEI Resources. Recombinant HA proteins
from A/New Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2),
and A/Vietnam 1203/2004 (H5N1) (H1, H3, andH5) were obtained from
Protein Biosciences (Meriden, CT). For live-virus infections, the follow-
ing influenza virus strains were used: A/New Caledonia/20/1999 (H1N1),
A/Wisconsin/67/2005 (H3N2), X-27 (a reassortant of A/Rockefeller Insti-
tute/5/57 [HA] A/NWS/34 [NA], subtype H2N1), A/Hong Kong/483/
1997 (H5N1), A/California/7/2009 NYMC (H1N1), and B/Malaysia/
2506/2004. The H1N1 and H3N2 seasonal virus strains and the influenza
B virus were a gift from Michel DeWilde and Robert Ryall of Sanofi Pas-
teur. TheH5N1 strainwas provided byNancyCox from theWorldHealth
Organization Influenza Reference Laboratory at the Centers for Disease
Control and Prevention (CDC), and the reassortant H2N1 strain was
obtained from BEI Resources. The 2009 pandemic H1N1 strain was pro-
vided by Alexander Klimov of the CDC.
All experiments using the live H5N1 strain were performed in a bio-
safety level 3 (BSL3) laboratory of the University of Massachusetts Medi-
cal School according to enhanced BSL3 guidelines (23a).
Study subjects. Blood samples were obtained from healthy adult do-
nors, and PBMCs were purified by Ficoll-Hypaque density gradient cen-
trifugation as previously described. To determine the HLA class II typing
of these donors, DNA from either PBMCs or autologous B lymphoblas-
toid cell lines (BLCLs) were extracted using the Puregene DNA purifica-
tion kit (Gentra Systems, Minneapolis, MN). For donors YD10, YD12,
and YD13, high-resolution HLA class II typing was performed using the
Applied Biosystems (Foster City, CA) high-resolution typing system.
HLA class II typing for the rest of the donors described in this paper was
done using the Olerup (Stockholm, Sweden) HLA-DR SSP kit.
IFN- ELISPOT. Enzyme-linked immunospot (ELISPOT) assays
were performed as previously described (4). Briefly, cryopreserved
PBMCs (2  105 to 2.5  105 cells per well) were seeded onto poly-
vinylidene difluoride membrane 96-well plates (Millipore, Bedford, MA)
precoated with 5 g/ml anti-IFN- monoclonal antibody (clone D1K;
Mabtech, Cincinnati, OH) in the presence or absence of peptide or pep-
tide pools. Phytohemagglutinin (Sigma-Aldrich, St. Louis, MO; 1:100)
was used as a positive control. After 18 to 24 h of incubation, the cells were
removed by washing with phosphate-buffered saline (PBS) plus 0.05%
Tween 20. Secondary biotinylated anti-IFN- monoclonal antibody
(clone 7-B6-1; Mabtech) was added at 2 g/ml and the plates were incu-
bated for 2 h at room temperature. The plates were washed again, and
IFN- was detected with avidin-peroxidase (3420-2H; Mabtech) and a
substrate kit (NovaRed; Vector Laboratories, Burlingame, CA). The fre-
quency of IFN--producing cells was determined by using the Immuno-
Spot S4 Pro Analyzer and the ImmunoSpot Academic V.4 Software (Cel-
lular Technologies Ltd., Shaker Heights, OH). Experiments were
performed in triplicate wells.
To determine the phenotype of IFN--producing cells in ELISPOT,
we depleted PBMCs of CD4 or CD8 cells as previously described (4).
Briefly, negative selection was done by using anti-CD4 or anti-CD8 anti-
body-coated magnetic beads from the MACS cell purification system
(Miltenyi Biotec, Bergisch Gladbach, Germany), which resulted in about
80 to 85% purity. The selected cells were then processed according to the
manufacturer’s protocol and were used in IFN- ELISPOT.
Generation of T cell lines. Influenza A virus-specific T cell lines were
established using a limiting-dilution assay, as previously described (4).
Briefly, PBMCs that were previously stimulated with the peptide(s) of
interest in culture for at least 14 days were plated at a concentration of 1,
3, 10, or 30 cells per well in 96-well round-bottom microtiter plates in 50
l of AIM-V medium supplemented with 10% fetal bovine serum (FBS)
(AIM-V-10), 50U interleukin 2 (IL-2), and a 1:1,000 dilution of anti-CD3
monoclonal antibody 12F6 (a gift from Johnson Wong) and 1  105
irradiated (3,500 rads) allogeneic PBMCs/well. On day 7, 50 l of fresh
AIM-V-10 and 50U IL-2 were added, and on day 14, fresh AIM-V-10 and
IL-2, 1 105 irradiated allogeneic PBMCs/well, and a 1:1,000 dilution of
the anti-CD3 12F6were added. The cells were assayed for cytolytic activity
using 51Cr assays between days 21 and 28. Cells from wells with influenza
A virus peptide-specific cytolytic activity (specific killing of 10% and
above at a peptide concentration of 10 g/ml) were expanded to 48-well
plates.
Preparation of APCs for 51Cr release assays and ICS. Autologous
BLCLs were established by taking donor PBMCs and culturing themwith
Epstein-Barr virus, as previously described (34). The BLCLs were either
infected with influenza virus or pulsed with peptide (4). Briefly, virus-
infected target BLCLswere incubated for 18 h at 37°C and radiolabeled for
51Cr release assays or were used as antigen-presenting cells (APCs) in
intracellular-cytokine staining (ICS). In experiments using inactivated
virus, influenza virus was heat inactivated in a water bath at 60°C for 30
min (42) prior to incubation with autologous BLCLs. For peptide-pulsed
targets, 10g/ml of peptidewas added to autologous BLCL suspensions as
described previously (4), unless otherwise indicated.
51Cr release assay.T cell lines or bulk culture effector cells were added
to 1.5 103 51Cr-labeled target cells at an effector-to-target (E:T) ratio of
10 unless otherwise indicated. After incubation for 4 to 6 h at 37°C, su-
pernatants were harvested (Skatron Instruments, Sterling, VA), and
percent specific immune lysis was calculated as follows: [(experimen-
tal release  spontaneous release)/(maximum release  spontaneous
release)]  100. Spontaneous lysis—given by the following formula:
Babon et al.
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(spontaneous release/maximum release) 100—was30% in all assays.
Peptide-pulsed target cells tended to have lower spontaneous lysis than
virus-infected target cells. All experiments were performed in triplicate
wells. Uninfected and non-peptide-pulsed target cells were used as nega-
tive controls.
ICS.AT cell line derived from a limiting-dilution assaywas used as the
effector cells in ICS. The cells were washed and resuspended at 5  105
cells in RPMI 1640 medium supplemented with 10% FBS (RPMI 10).
Autologous BLCLswere used as APCs at an E:T ratio of 10 andwere added
to the effector cells. They were incubated for 1 h at 37°C in a 5% CO2
incubator, followed by an additional 5 h in the presence of Golgi plug (BD
Biosciences, San Jose, CA). The cells were then washed with fluorescence-
activated cell sorter (FACS) buffer (2% FBS and 0.1% sodium azide in
PBS) and stained using the Live/Dead aqua fixable dead cell stain kit
(Invitrogen, Eugene, OR) to identify live and dead cells. The cells were
then stained for surface markers, such as CD3–allophycocyanin (APC)-
Cy7, CD8–peridinin chlorophyll protein (PerCP)-CY5.5, CD19/CD14-
phycoerythrin (PE)-Cy7 (BD Biosciences, San Jose, CA), or CD4-Pacific
Blue (eBiosciences, San Diego, CA) for 30 min at 4°C. After washing with
FACS buffer, the cells were fixed and permeabilized with Cytofix/Cy-
toperm (BD Biosciences, San Jose, CA) and stained for the intracellular
cytokine IFN- (Alexa 700 conjugate; BD Biosciences) or tumor necrosis
factor alpha (TNF-) (APC conjugate; BD Biosciences, San Jose, CA) for
30 min at 4°C. The cells were then washed with Permwash buffer (BD
Biosciences, San Jose, CA) and resuspended in 1 BD Stabilizing Fixative
(BD Biosciences, San Jose, CA) for flow cytometric analysis. Multiparam-
eter flow cytometric analyses were performed using the Aria flow cytom-
eter. The number of events collected per experiment varied from 100,000
to 300,000. List mode data files were analyzed using FlowJo (version 6.3;
TreeStar 6, Inc., Ashland, CA). Graphs were plotted as dot plots of
TNF-- versus IFN--producing T cells in the gated live CD3CD4 cell
population.
Peptide binding assay. A fluorescence polarization assay was used to
determine the binding affinities of HA peptides containing the fusion
peptide sequence to theHLA-DR1molecule. TheHA306-318 peptide probe
(acetyl [Ac]-PRFVKQNTLRLAT) was synthesized (21st Century Bio-
chemicals, Marlboro, MA) and labeled with Alexa 488-tetrafluorophenyl
ester (Invitrogen, Eugene, OR). Soluble recombinant HLA-DR1was pre-
pared as previously described (26). Peptide-free HLA-DR1 (100 nM) was
mixed togetherwith theAlexa 488-HApeptide probe (25 nM) and various
concentrations of unlabeled competitor peptide (from 0.08 to 20 M).
The reactions were done in triplicate wells for each competitor peptide
concentration in a 96-well format and incubated for 3 days at 37°C in
binding buffer (pH 5.5) containing protease inhibitors and 0.5 mg/ml
octylglucoside. Fluorescence was detected using the Alexa 488-fluores-
cence polarization measurement protocol of the Perkin Elmer 2030 Ex-
plorer multilabel plate reader. Fifty percent inhibitory concentrations
(IC50s) were obtained by fitting a competition curve of percent inhibition
of peptide probe versus the logarithmic value of the concentration of
competitor peptide using GraphPad Prism version 5.04.
RESULTS
Donors who were not exposed to the H2N2 virus have T cell
responses toH2HA.Wewere originally interested in looking at T
cell memory responses to the H2 HA in individuals who were
previously exposed to the H2N2 virus, i.e., those who were alive at
the time of the 1957 pandemic and during the years H2N2 viruses
circulated up to the emergence of H3N2 in 1968. Our group (4)
and others (16, 64) previously found individuals who had H5 HA
T cell responses: therefore, we hypothesized that prior immunity
to H2 HA may contribute to this cross-reactive T cell response
because H2 and H5 HA sequences are the closest based on their
phylogeny (25). IFN- ELISPOT assays were done to quantify the
H2 HA memory T cells using H2 HA peptide pools to be able to
compare the responses of older (born before 1957) and younger
(born after 1968) donors. We expected to detect responses to H2
HA in the PBMCs of the older group, but not in the younger
donors. Indeed, 7 of the 11 older individuals’ T cells had IFN-
responses to at least one peptide pool (Fig. 1A), although for most
donors, the spot-forming-cell (SFC) values are modestly above
our cutoff for a positive IFN- response (20 SFCs/106, 3 standard
deviations of the negative-control wells [PBMCs without pep-
tides], which we previously set for our ELISPOT assays [4]). To
our surprise, younger donors’ PBMCs had responses to H2 HA
peptide pools, as well (Fig. 1B, pool 7 and pool 9).When we tested
the individual peptides in these pools, the PBMCs of donor YD02
had IFN- responses to H2 HA339-355 (Fig. 1C). The PBMCs of
donor YD06 also had similar responses, although the numbers of
spots were below the cutoff for both pool 9 and the H2 HA339-355
peptide. The PBMCs of donor YD04 had responses to H2
HA387-403 (Fig. 1D).
The IFN- response to the H2 HA339-355 peptide is well con-
served in other HA subtypes and is mediated by CD4 cells.
Donors YD02 andYD06were born in 1977 and 1981, respectively,
well after 1968, when H2N2 was last detected in the human pop-
ulation. We thought that the IFN- responses in the PBMCs of
these donors might be due to cross-reactive memory T cell re-
sponses generated by exposure to more recently circulating sea-
sonal influenza virus strains of the H1N1 andH3N2 subtypes.We
tested the corresponding peptides located in the H1, H3, and H5
HAs and found that the donors’ T cells responded to these pep-
tides (Fig. 2A). Peptides that induced IFN- production in
PBMCs from donor YD02 all contained the RGLFGAIAGFIEGG
(RGIFGAIAGFIENG in H3) amino acid sequence (Table 1),
which maps to the fusion peptide of the influenza virus HA (15).
Although the H3 HA338-354 peptide, which lacks IENG at its C
terminus, induced IFN- secretion, other peptides without IEGG
at their C termini, such asH2HA337-349 andH5HA339-355, did not.
CD4 or CD8 cells were depleted fromYD02 PBMCs to identify
the cell population that was responding to the peptides. The de-
pleted PBMCswere tested against the peptides inH1, H2, H3, and
H5 HAs that contained the entire RG(L/I)FGAIAGFIE(G/N)G
amino acid sequence. IFN- was produced in the presence of
CD4 cells in the PBMCs, indicating that the peptide is presented
by the MHC class II molecule (Fig. 2B).
In vitro-generated CD4 T cell lines specific to H2 HA339-355
recognize autologous target cells infected with various influ-
enza A and B viruses. To further characterize the conserved
epitope, we generated bulk culture lines by stimulating PBMCs
from YD02 with the H2 HA339-355 peptide. A limiting-dilution
assay at 1, 3, or 10 cells per well in a 96-well plate was then set up to
isolate a T cell line(s) specific to H2 HA339-355. Although cytotox-
icity may not be a major function of virus-specific CD4 T cells,
we had previously established both CD8 and CD4 T cell lines
from a limiting-dilution assay using a standard 51Cr release assay
(4, 22, 27, 35, 40, 41, 50). Thus, after establishment, we initially
characterized candidate T cell lines by looking at their ability to kill
autologous BLCL targets pulsed with the cognate peptide. We
found a T cell line that was able to kill target cells pulsed with H2
HA339-355 in a dose-dependent manner (Fig. 3A). When we per-
formed surface staining, more than 97% of the live CD3cells
were CD4 (see Fig. S1 in the supplemental material). The CD4
T cell line was also tested against target cells pulsed with corre-
sponding peptides in H1, H3, and H5 HAs (Fig. 3B). As expected,
Cross-Reactive CD4 T Cell Epitope to Inﬂuenza Virus A/B
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thisH2HA339-355-specific T cell linewas able to lyse those peptide-
pulsed target cells. The pattern of lysis is also consistent with the
IFN- responses to the peptides shown in Fig. 2A (summarized in
Table 1). The H2 HA339-355 T cell line was also able to lyse target
cells pulsed with various recombinant HA proteins (see Fig. S2 in
the supplemental material).
To determine if the T cell line can kill virus-infected targets, we
infected autologous BLCLs with seasonal H1N1 and H3N2
strains, including a 2009 pandemic H1N1 strain, an H5N1 strain,
and a reassortant H2N1 strain. All of the virus-infected target cells
were lysed specifically by the H2 HA339-355 T cell line (Fig. 3C).
The fusion peptide sequence is well conserved in influenza vi-
rusHA, including BHA (15). Therefore, we asked if this T cell line
is able to recognize this sequence in the influenza B virus HA
protein, as well. Indeed, the T cell line killed both peptide-pulsed
and B virus-infected targets (Fig. 3D), indicating that this CD4T
cell epitope is also presented in the context of an influenza B virus
infection. These results also confirm the IFN- responses we saw
in ELISPOT for the B HA peptide containing the fusion peptide
sequence (Table 1).
The H2HA339-355 T cell line produces IFN- and TNF-. In-
fluenza virus-specific CD4 T cells have been shown to produce a
variety of cytokines, including IFN- and TNF- (49). We per-
formed an ICS assay to identify the cytokines produced by the H2
HA339-355 T cell line upon stimulation with either peptide-pulsed
or virus-infected target cells. The T cell line was incubated with
either peptide-pulsed or virus-infected autologous BLCLs as
APCs in the presence of GolgiPlug for 6 h. The live CD3CD4 T
cells (95%) produced both IFN- and TNF- when they were
stimulated with autologous BLCLs that were pulsed with the fu-
sion peptide epitope, but not with the negative-control HLA-A2-
restricted M158-66 epitope peptide (Fig. 4A). Autologous BLCLs
were also infected with seasonal and pandemic H1N1 and H3N2
strains, a reassortant H2N1, and an influenza B virus strain and
were used to stimulate theH2HA339-355 T cell line. Aswith peptide
stimulation, the CD4 T cells were double-positive for IFN- and
TNF-, withmore than 50%of the cells producing both cytokines
in response to influenza virus infection (Fig. 4B), but not against
target cells infectedwith vaccinia virus strainWR (at amultiplicity
of infection [MOI] of 1) or pulsed with the vaccinia virus B5R
FIG 1 IFN- responses of various donor PBMCs to H2 HA peptide pools and individual peptides. (A and B) Older (A) and younger (B) donor PBMCs were
tested in ELISPOT against H2 HA peptide pools to quantify and compare the IFN- responses to H2 HA. Each peptide pool contained 9 or 10 nonoverlapping
peptides spanning the H2 HA, and each point represents an individual donor. Due to the limited number of PBMCs collected from each donor, the ELISPOT
peptide pool screen was done only once, with each pool tested in triplicate wells. Donor PBMCs that had responses to the peptide pools were screened against
individual peptides contained in those pools. The peptide pools and individual peptides were tested in three replicate wells with 200,000 to 250,000 cells per well.
(C and D) YD02 and YD06 were screened against the individual peptides of H2 HA pool 9, while YD04 was screened against the individual peptides of H2 HA
pool 7. Values are given as SFCs/106, which is the mean number of spots from triplicate wells. The data presented are adjusted for background spots given by the
wells that had only PBMCs andmedium. The error bars indicate the standard errors of the mean of triplicate wells. All donors responded to the positive control,
PHA (mean	 2,246.8 SFCs/106). Negative-control wells had mean values of 3.5 SFCs/106 for the older donors and 1.7 SFCs/106 for the younger donors. The
dotted lines indicate the cutoff SFC value we established previously. The final concentration of peptide used for all experiments was 2 g/ml per peptide.
Babon et al.
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protein (Fig. 4C). The H2 HA339-355 T cell line also responded to
APCs that were mixed with heat-inactivated influenza virus, sug-
gesting that extracellular influenza virus antigens are taken up
through the endocytic pathway and undergoMHCclass II presen-
tation (Fig. 4D).
The HLA alleles of human donors who have ex vivo re-
sponses to the H2 HA339-355 epitope. The two donors, YD02 and
YD06, that responded to the H2 HA339-355 peptide in our initial
ELISPOT experiments both expressed the HLA-DRB1*09 allele.
We therefore tested additional donor PBMCs that had the HLA-
DRB1*09 allele. All five of the additional HLA-DRB1*09-express-
ing donors’ cells had ex vivo IFN- responses to the HA peptides
containing the RG(L/I)FGAIAGFIE(G/N)G sequence of the fu-
sion peptide (Table 2). To confirm that the T cells responding to
the fusion peptide epitope inHLA-DRB1*09 donorswereCD4T
cells, we performed depletion of CD4 or CD8 T cells from the
PBMCs of donors YD09 and YD12, as we did with the PBMCs of
donor YD02 (Fig. 2B). CD4T cell depletion, but not CD8T cell
depletion, resulted in loss of the IFN- response in ELISPOT (Ta-
ble 3).
An MHC class II binding motif prediction algorithm (http:
//tools.immuneepitope.org/analyze/html/mhc_II_binding.html)
from the Immune Epitope Database (IEDB) (http://www
.immuneepitope.org) (53) identified IESRGLFGAIAGFIE as a top
4.52% binder to the HLA-DRB1*09:01 molecule, as well as ESRG
LFGAIAGFIEG (top 4.98%) and SRGLFGAIAGFIEGG (top
5.32%), among peptides in the HA protein of the A/Japan/305/
1957 (H2N2) strain. An L¡I or G¡N change in the H3 sequence
FIG 2 IFN- responses to corresponding peptide sequences in other A HAs. (A) YD02 and YD06 PBMCs were screened against the corresponding 17-mer
peptides in H1, H3, and H5 HAs that included the partial or the entire RGLFGAIAGFIE(G/N)G amino acid sequence in ELISPOT. The data are representative
of two independent ELISPOT experiments. (B) YD02 PBMCs were depleted of either CD4- or CD8-expressing cells by negative selection using magnetic beads
and were used in ELISPOT assays to determine the phenotype of IFN--responding cells. SFC values for the positive control, PHA, were greater than 2,000
SFCs/106, while negative-control SFCs were between 2 and 3/106. The error bars indicate the standard errors of the mean of triplicate wells. The dashed lines
indicate the cutoff SFC value we established previously.
TABLE 1 Summary of influenza A/HA subtypes and B/HA peptides containing the conserved RG(L/I)FGAIAGFIE(G/N)G sequence of the fusion
peptide and the corresponding responses of donor YD02 T cells in ELISPOT and 51Cr release assays
Influenza A virus strain Peptide name Peptide sequencea YD02 PBMCs in ELISPOTb T cell line from YD02 in CTLsc
A/Japan/305/1957 (H2N2) H2 HA337-349 IESRGLFGAIAGF  
H2 HA339-355 SRGLFGAIAGFIEGGWQ  
H2 HA345-361 AIAGFIEGGWQGMVDGW  
A/NewCaledonia/20/1999 (H1N1) H1 HA340-356 IQSRGLFGAIAGFIEGG  
H1 HA346-362 FGAIAGFIEGGWTGMVD  
H1HA352-368 FIEGGWTGMVDGWYGYH  
A/New York/384/2005 (H3N2) H3 HA338-354 NVPEKQTRGIFGAIAGF  ND
H3 HA344-360 TRGIFGAIAGFIENGWE  
H3 HA350-366 AIAGFIENGWEGMVDGW  
A/Thailand/4(SP-528)/2004 (H5N1) H5 HA339-355 RERRRKKRGLFGAIAGF  
H5 HA345-361 KRGLFGAIAGFIEGGWQ  
H5 HA351-367 AIAGFIEGGWQGMVDGW  
B/Nanchang/12/1998 (Influenza B) B/HA354-370 PAKLLKERGLFGAIAGF  
B/HA360-376 ERGLFGAIAGFIEGGWQ  
a The amino acids that comprise the conserved RG(L/I)FGAIAGFIE(G/N)G sequence are underlined.
b Summary of ELISPOT results from Fig. 2A, with the exception of the B/HA peptides, which were determined in a separate experiment. A plus sign is defined as an ELISPOT
response greater than or equal to 20 SFC/106.
c Summary of CTL results from Fig. 3B. A plus sign is defined as greater than or equal to 15% specific lysis in 51Cr release assays. ND, not done.
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(RGIFGAIAGFIENG) did not affect the predicted binding scores.
Donor YD08 also had ex vivo responses to the H2 HA339-355
epitope but did not have the HLA-DRB1*09 allele (Table 2), sug-
gesting the promiscuity of the epitope. Treatment of autologous
BLCLs with blocking antibodies to HLA-DQ and -DP did not
inhibit specific immune lysis by the H2 HA339-355 T cell line, while
anti-HLA-DR blocked antigen presentation by as much as 70%
(data not shown).
We also performed a fluorescence polarization assay to further
confirm the affinity of the peptide epitope for the HLA-DR mol-
ecule. Since the HLA-DRB1*09molecule was not available for the
assay, we used the HLA-DRB1*01:01 (HLA-DR1) molecule,
which has a similar peptide bindingmotif in position 1 (19, 70). In
addition, this H2 HA339-355 peptide was also predicted to be a top
9.36% binder to HLA-DRB1*01:01 using the IEDB MHC class II
binding motif prediction algorithm (http://tools.immuneepitope
.org/analyze/html/mhc_II_binding.html; 53). We used overlap-
ping H5 HA peptides containing parts of the fusion peptide se-
quence to determine the optimal 17-mer that can bind to HLA-
DR1 (see Fig. S3 in the supplemental material). The H5 HA345-361
(KRGLFGAIAGFIEGGWQ) had an IC50 of 
893 nM, which in-
dicates that this 17-mer sequence can bind toHLA-DR1, although
modestly compared to HA306-318 (see Table S1 in the supplemen-
tal material).
DISCUSSION
We established a human CD4 T cell line recognizing a cross-
reactive epitope that is conserved among the different HA types of
influenza A virus, and also the HA of influenza B virus. The
epitope is located in the fusion peptide sequence of the influenza
virus HA. We also found by ELISPOT that adult donors’ T cells
had ex vivo IFN- responses to the different influenza A virus HA
and B virus HA peptides that contain the RG(L/I)FGAIAGFIE
(G/N)G sequence of the fusion peptide. Analysis of evolutionarily
conserved sequences in the different influenza A virus compo-
nents revealed that the FGAIAGFIE sequence of the fusion peptide
is the only region in the HA protein that is 98 to 100% conserved
in strains of the different human and avian influenza virus sub-
FIG 3 Characterization of the H2 HA339-355-specific T cell line using a standard
51Cr release assay. (A) A dose response curve of the T cell line to H2 HA339-355
peptide was determined using a standard 51Cr release assay. (B and C) The T cell line was also used as effector cells against autologous BLCLs pulsed with the
corresponding peptides in other A/HAs (B) or infected with various influenza A virus strains (C). A 51Cr release assay using H5N1-infected targets was done in
a separate experiment under enhanced biosafety level 3 conditions (light-gray bars). (D) Responses to the corresponding B HA peptides and B virus infection
were also determined in a 51Cr release assay. The percent specific immune lysis was determined by subtracting the percentage of lysis of unpulsed targets from that
of the peptide-pulsed targets. H2 HA339-355-pulsed target cells were used as a positive control. All assays were performed in triplicate.
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types that circulated between 1997 and 2006 (39), as well as in
influenza B viruses (12). This conservation is probably due to the
critical role of the domain in triggering fusion and destabilizing
target membranes during the fusion process (15). A previous
study using a mouse model showed that the stability of the fusion
peptide sequence enhanced the immunogenicity of CD4 T cell
epitopes adjacent to the fusion domain (56). Our findings show
that the fusion peptide itself contains a CD4 T cell epitope, as
well.
The CD4 T cell epitope that we have characterized is likely to
be restricted by the HLA-DRB1*09 allele, based on our results,
although it could possibly bind to other HLA-DR molecules, as
well, as was previously shown for the HA306-320 CD4
 T cell
epitope (84).We also detected ex vivoT cell responses to the fusion
peptide in one donor who is not HLA-DRB1*09, indicating that
the fusion peptide epitope is promiscuous. In fact, we have shown
that this CD4 T cell epitope peptide can bind to the HLA-DR1
molecule in a biochemical assay (see Fig. S3 in the supplemental
material). Moreover, all seven of the HLA-DRB1*09 donors’
PBMCs have ex vivo IFN- responses to the fusion peptide epitope
in ELISPOT. The ethnic origin of theHLA-DRB1*09 allele is Cau-
casoid and Oriental (http://www.ebi.ac.uk/cgi-bin/imgt/hla/get
_allele.cgi?DRB1*09:01:02), and recent studies have shown that
this allele is frequently present in East and Southeast Asian popu-
lations (52, 55, 63, 85), in particular the Han Chinese, who com-
prise more than 90% of the population of mainland China. In a
high-resolution genotyping of the HLA-DRB1 locus in individu-
als from Jiangsu Province, China, HLA-DRB1*09:01 was themost
frequent allele (15.69%) (52). Another possibility is that the
epitope is also restricted by other HLA-DR haplotypes. The HLA-
DR9 serotype has been shown to be in linkage disequilibriumwith
HLA-DR53 (HLA-DRB4*01:01) (reviewed in references 2, 5, and
37) (we determined only the HLA-DRB1 typing of the donor
PBMCs), and it has been reported that one out of six HLA-
DRB1*09:01-binding peptides can bind to HLA-DRB4*01:01
(44). Using the IEDB MHC class II binding motif prediction al-
FIG 4 Cytokine profile of the H2 HA339-355-specific T cell line upon stimulation with peptide-pulsed or virus-infected autologous BLCLs. (A and B) The H2
HA339-355-specific T cell line was incubated with either influenza virus peptide-pulsed (A) or influenza virus-infected (B) BLCLs for 5 to 6 h in the presence of
Golgi plug. The T cells were then stained with surface marker and intracellular-cytokine fluorophore-conjugated antibodies to determine the cytokine profile
after stimulation. (C) In a separate experiment, the autologous target cells were pulsed with recombinant vaccinia B5R protein or infected with vaccinia virus
(strainWR;MOI of 1) to demonstrate the specificity of theH2HA339-355 T cell line. (D) The T cell line was also incubatedwith autologous target cells pulsedwith
influenza virus HA peptides containing the RG(L/I)FGAIAGFIE(G/N)G sequence and with target cells either infected with live virus (seasonal H1N1) or mixed
with heat-inactivated influenza virus (H.I. seasonal H1N1). The peptide and recombinant protein concentration used in all experiments was 10g/ml. The plots
were gated for live, CD3, CD19, CD4/CD8 cells. The cytokine responses to peptide shown in panel A are representative of one out of three experiments.
Those in panels B, C, and D were determined in separate single experiments.
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gorithm, the fusion peptide sequence is predicted to be among the
top 
50 to 80% of binders to HLA-DRB4*01:01 compared to
HLA-DRB1*09:01, where it is predicted to be among the top 5%
of binders in theHAprotein. This indicates that the fusion peptide
is more likely to bind to theHLA-DRB9*01:01molecule, since the
predicted top 10% highest-scoring peptides are considered to be
good binders (79).
Therewere notable differences in the T cell responses we saw to
the various HA peptides. The H2 HA337-349, H5 HA339-355, and B
virus HA354-370 peptides, which lack the IEGG sequence at their C
termini, were not positive in our ELISPOT assays, while the H3
HA338-354 peptide, which also lacks the IEGG sequence, was posi-
tive (Table 1 and Fig. 2A).When theH3HA338-354 peptide and the
H3 HA344-360 peptide were compared (Fig. 2A), the H3 HA344-360
peptide, which has the IENG sequence, stimulated more IFN--
producing cells than the H3 HA338-354 peptide without the IENG
sequence (asmentioned inResults, an L¡I orG¡Nchange in the
H3 sequence did not affect the predicted binding scores). These
results suggest the presence of at least two overlapping epitopes,
which is consistent with the peptide binding prediction that there
are three potential overlapping peptides binding to the HLA-
DRB1*09:01 molecule.
More CD8 T cell epitopes to influenza virus have been de-
fined than CD4 T cell epitopes. The CD4 T cell epitope PKYV
KQNTLKLAT was one of the first human CD4 T cell epitopes
identified (45), and initially, it was thought to be immunodomi-
nant (46, 84). It has been used in several studies to characterize
and describe the CD4 T cell responses to influenza virus (11, 17,
29, 48, 54, 66). Subsequent studies have shown that a number of
HA-derived CD4 T cell epitopes can be recognized in infected
individuals (30) and in healthy adults (4). Several of these HA-
derived CD4 T cell epitopes are restricted by HLA-DR1 (http:
//www.immuneepitope.org; 10, 53). In addition, a study looking
at CD4 T cell epitopes in the influenza virus HA using an HLA-
DR1 transgenic-mouse system show the diversity of the T cell
response to HA and that several of these epitopes are located in
conserved regions of the HA (57). The same group also looked at
the CD4T cellmemory phase and found that, although the over-
all memory response to influenza virus remains diverse and di-
rected to several influenza virus proteins, there was a modest but
reproducible shift towardHA-derived epitopes (58). This suggests
that a majority of CD4 T cell responses are directed to influenza
virusHA, andmost of them are in regions that are structurally and
functionally conserved. A possible explanation could be that re-
peated exposure to different virus strains through infection or
immunization may selectively stimulate T cells specific to the
epitopes located in conserved regions.
The CD4 T cell epitope that we have described here is also
conserved in the HA of influenza B viruses. Influenza A and B
viruses are almost the same in structure by electron microscopy,
with both having the same number of gene segments that encode
the viral proteins (65). At the amino acid level, however, sequence
similarities are only 12 to 39% for all proteins, except for basic
polymerase 1, which is 60% similar (comparisons were performed
betweenA/NewYork/348/2003 [H1N1] and B/Florida/4/2006 us-
ing CLUSTAL W Multiple Sequence Alignments [http://www
.genome.jp/tools/clustalw/] for internal proteins). Influenza B vi-
rus has a larger genome, and its membrane channel protein is
quite different from that of influenza A virus (65). Although a
number of CD4 and CD8 T cell epitopes in influenza A viruses
TABLE 2 Ex vivo IFN- responses to the fusion peptide epitope in healthy adult donors
Donor HLA class II typing
SFC/106a
H1 H2 H3 H5 B/HA
YD02 DRB1*03, DRB1*09:01:02 22.7 1.7 26.7 2.7 46.7 2.7 32 5.9 14 1.5b
YD06 DRB1*01, DRB1*09:01:02 22.7 4.0 28 3.2 36 2.9 36 4.2 NDc
YD08 DRB1*04, DRB1*13 22.2 2.7 60 4.0b 66.7 2 22.2 3 7.4 2.3
YD09 DRB1*09, DRB1*12 33.3 4 46.7 5.5 41.7 3.1 31.7 3.1 48.3 6.6
YD10 DRB1*09, DRB1*14 101.7 4.2 96 10.5 84.7 11.8 71.2 7 81.4 9.2
YD11 DRB1*01, DRB1*09 68 7.6 40 2.7 72 7 68 3.6 34.7 3.5
YD12 DRB1*04:06, DRB1*09:01 103.3 20.4 56.7 2.1 53.3 6.4 40 7 48.3 2.9
YD13 DRB1*04, DRB1*09 ND 66.7 6.1 ND 30 3.5 ND
a The SFC/106 values indicate the IFN- response of the donor to the HA peptide containing the conserved RG(L/I)FGAIAGFIE(G/N)G sequence. The cutoff for a positive response
is 20 SFC/106. The ELISPOT was performed once for each donor PBMC using triplicate wells to test the HA peptides. The standard error of the mean of triplicate wells was
calculated for each HA peptide.
b Performed in a separate experiment.
c ND, not done.
TABLE 3 Ex vivo IFN- responses to the fusion peptide epitope in CD4- or CD8-depleted PBMCs
Donor
H5 HA345-361 peptide (SFC/10











YD03b 2.7 0.6 0 4 0 0 4 2.1
YD09 37.3 12.4 0 61.3 1.5 18.7 2 0 0.6 60 2.1
YD12 14.7 5.8 0 120 9.5 83.3 27.6 0 165.3 18.2
a The SFC/106 values indicate the IFN- response of the donor to the HA peptide containing the conserved RG(L/I)FGAIAGFIE(G/N)G sequence. The cutoff for a positive response
is 20 SFC/106. The ELISPOT was performed once using triplicate wells for each HA peptide, and the standard errors of the mean of triplicate wells were calculated.
b Donor YD03 is a nonresponder to the fusion peptide epitope and is used as a negative PBMC control.
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have been identified using different strategies (IEDB [http://www
.immuneepitope.org]), only a few T cell epitopes have been iden-
tified in influenza B viruses. An HLA-A*0201-restricted CD8 T
cell epitope located in the NP (NP85-94) has been studied most
extensively (60, 61, 67). There are also two HLA-B8-restricted
CD8 T cell epitopes, also located in the NP (NP30-38 and
NP262-271), that have been identified (62) and one HLA-
DRB1*0101-restricted CD4 T cell epitope that is located in the
HA (HA308-320) (62). These epitopes were identified by generating
peptides from these two viral proteins based on prediction algo-
rithms and using them to stimulate cytotoxic T lymphocyte re-
sponses in PBMCs from a limited number of donors. In addition,
the HA protein sequence of influenza B virus has only 26 to 27%
sequence similarity with the H1, H3, and H5 HAs of influenza A
virus (BLAST [http://blast.ncbi.nlm.nih.gov/Blast.cgi] results
comparingHA protein sequences of B/Florida/4/2006 and A/New
Caledonia/20/1999 [H1N1], A/New York/384/2005 [H3N2], and
A/Thailand/SP [528]/2004 [H5N1]).
The ex vivo responses to the fusion peptide epitope in our do-
nor PBMCs suggest that this CD4T cell response is present in the
memory compartment andmay be attributed to prior exposure to
influenza virus antigens via infection or vaccination. This type of
cross-reactive immunity is called influenza virus heterosubtypic
immunity (HSI) (reviewed in reference 33). HSI has been demon-
strated in animal experiments but is challenging to demonstrate in
humans. The existing literature on the topic includes a retrospec-
tive analysis (23) and an epidemiological study done at the brink
of the 1957 H2N2 pandemic that compare immune responses in
individuals who had prior H1N1 infection and their propensity to
become ill after exposure to the novel H2N2 virus (69). Both stud-
ies suggest the impact of accumulated HSI in the event of a pan-
demic, where partial protection againstH2N2was seen in individ-
ualswhowere previously infectedwithH1N1. Epstein suggests the
contribution of CD4 and CD8 T cells in mediating HSI, since
these individuals did not have antibodies to H2 HA that could
have protected them from H2N2 infection. It is interesting to
speculate that a subset of the population could have maintained a
memory response to this particular HA epitope by repeated expo-
sure to influenza virus antigens via natural infection and/or vac-
cination. In light of the recent influenza pandemic, HSI may be a
contributing factor to its mildness and lower mortality rates com-
pared to previous pandemics. Aside from the detection of preex-
isting antibodies to HA in older individuals (38), there was also
preexisting T cell immunity to the pandemic strain, as exemplified
by the presence of bothCD8 andCD4T cell epitopes generated
from previous encounters with seasonal influenza virus strains (1,
18, 28, 59, 82). Thus, HSI significantly impacted the course of the
recent influenza pandemic.
Although CD4 T cells may be dispensable in viral clearance
and protection, as shown in mouse studies, optimal humoral and
cellular immunities to influenza require the activation of CD4 T
helper cells (reviewed in reference 9). Indeed, a recent study by
Wilkinson and colleagues demonstrated that preexisting influ-
enza virus-specific CD4 T cells were correlated with protection
against influenza virus challenge in humans (80). McKinstry and
colleagues suggest several mechanisms by which CD4 T cells can
contribute to heterosubtypic immunity (reviewed in references 49
and 75). Influenza virus-specific CD4 T cells can provide help to
B cells and cross-reactive CD8 T cells during infection, and they
may also regulate early innate immune responses by indirectly
upregulating inflammatory cytokines and chemokines during the
early stage of infection (73). They can also act as antiviral effectors
themselves during a heterosubtypic infection (49). CD4 T cells
can also have a cytotoxic effector function via a perforin-mediated
mechanism in a mouse model of influenza virus infection (8).
Teijaro et al. have shown thatmemory CD4T cells specific to the
H1N1 influenza virus provide a protective immune response in
the lungs after a lethal challenge in mice, suggesting that CD4 T
cells can be effectors as well, independent of T helper mechanisms
(77).
Cross-reactive CD4 T cells may also play important roles in
generating robust antibody responses to influenza virus, although
the mechanisms are still not clear. With the recent identification
and characterization of several cross-reactive antibodies to the
more conservedHA2 domain or the stalk region ofHA (14, 21, 74,
81) and the novel approach of generating influenza virus vaccines
based on the stalk region (including fusion peptide) (72), the pres-
ence of the cross-reactive CD4 T cell epitope in the fusion pep-
tide may be helpful to induce higher levels of cross-reactive anti-
body responses, at least for individuals with the HLA-DRB1*09
allele (and other alleles with similar peptide binding motifs). Sev-
eral groups have also shown that these cross-reactive antibodies
can be detected in human sera (13, 43, 78). Specific activation of
these helper T cells should be considered in designing or improv-
ing vaccination strategies against influenza virus. CD4 T cell
epitopes tend to be more promiscuous than CD8 T cell epitopes
due to the nature of MHC class II molecules (36). This may be
advantageous when considering epitopes to be included in an im-
proved vaccine for influenza virus, sincemore than oneHLAmol-
ecule can present the peptide. In addition, a peptide conjugate
vaccine based on the fusion peptide of the precursor HA of the B
virus was shown to elicit protection in mice against lethal chal-
lenge of various strains of influenza B virus and can potentially be
extended to influenza A virus strains (7). It is also interesting to
note that a B cell epitope (3) and an HLA-A2-restricted CD8 T
cell epitope (32) have been previously described. A more recent
study examined the presence of HA2-specific antibodies in acute-
and convalescent-phase sera from adults with confirmed H3N2
infection (71). They found that a third (15/45) of the subjects had
antibodies specific to the N-terminal residues 1 to 38 of HA2,
which includes the fusion peptide sequence. These data indicate
that the fusion peptide of the influenza virus HA is a relevant
target of the immune response to influenza virus.
In conclusion, we have identified and described a cross-reac-
tive human CD4 T cell epitope in the influenza virus HA that is
highly conserved in all the influenza A and B virus HA proteins.
This epitope is recognized by individuals who have the HLA-
DRB1*09 allele. Our in vitro experiments show that the CD4 T
cell response to this epitope is characterized by the production of
IFN- and TNF-. To our knowledge, this is the first influenza
virus CD4 T cell epitope in the HA protein that is cross-reactive
to influenza A and B viruses. Although natural infection or stan-
dard vaccination may not induce strong T and B cell responses to
this very conserved epitope in the fusion peptide, it may be possi-
ble to develop a vaccination strategy to induce these CD4 T cells,
which are cross-reactive to both influenza A and B viruses.
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Volume 86, no. 17, p. 9233-9243, 2012. Page 9237, Table 1: Typographical errors in peptide sequences were introduced when Table 1
was assembled. Correct amino acid sequences for peptides B/HA354 –370 and B/HA360 –376 are “PAKLLKERGFFGAIAGF” and “ERGFF
GAIAGFLEGGWE,” respectively. Therefore, the conserved sequence should be “RG(L/I/F)FGAIAGF(I/L)E(G/N)G” instead of “RG
(L/I)FGAIAGFIE(G/N)G.”
We repeated the MHC class II binding motif prediction (http://tools.immuneepitope.org/analyze/html/mhc_II_binding.html) with
the correct peptide sequences and confirmed that these amino acid variations did not negatively affect the predicted binding scores.
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